NO327296B1 - Ny medisinsk anvendelse av 4α-acetoksy-2α-benzoyloksy-5β,20-epoksy-1β-hydroksy-7β,10β-dimetoksy-9-okso-11-taxen-13α-yl(2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylpropionat. - Google Patents

Ny medisinsk anvendelse av 4α-acetoksy-2α-benzoyloksy-5β,20-epoksy-1β-hydroksy-7β,10β-dimetoksy-9-okso-11-taxen-13α-yl(2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylpropionat. Download PDF

Info

Publication number: NO327296B1
Authority: NO; Norway
Prior art keywords: hydroxy; dose; brain; product; tert
Prior art date: 1998-08-17

Application number

NO20010654A

Other languages

English (en)

Norwegian (no)

Other versions

NO20010654D0 (no

NO20010654L (no

Inventor

Marie-Christine Bissery

Patricia Vrignaud

Simon Roberts

Clive Brealey

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-17

Filing date

2001-02-07

Publication date

2009-06-02

1998-08-17 Priority claimed from EP98115401A external-priority patent/EP0982027A1/en

2001-02-07 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2001-02-07 Publication of NO20010654D0 publication Critical patent/NO20010654D0/no

2001-02-07 Publication of NO20010654L publication Critical patent/NO20010654L/no

2009-06-02 Publication of NO327296B1 publication Critical patent/NO327296B1/no

Links

ZVAFCKLQJCZGAP-WDEREUQCSA-N (2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H]([C@@H](O)C(O)=O)C1=CC=CC=C1 ZVAFCKLQJCZGAP-WDEREUQCSA-N 0.000 title 1
238000011282 treatment Methods 0.000 claims description 20
210000004556 brain Anatomy 0.000 claims description 19
238000001990 intravenous administration Methods 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 3
230000002159 abnormal effect Effects 0.000 claims description 2
230000004663 cell proliferation Effects 0.000 claims description 2
150000001875 compounds Chemical class 0.000 description 26
239000000047 product Substances 0.000 description 25
238000000034 method Methods 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
241000699670 Mus sp. Species 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 12
208000005017 glioblastoma Diseases 0.000 description 12
YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 9
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000008569 process Effects 0.000 description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
239000002585 base Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
239000002168 alkylating agent Substances 0.000 description 7
229940100198 alkylating agent Drugs 0.000 description 7
-1 haloacetic acid Chemical class 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
238000010511 deprotection reaction Methods 0.000 description 5
238000002513 implantation Methods 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229960004679 doxorubicin Drugs 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000011160 research Methods 0.000 description 4
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
238000012360 testing method Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000003213 activating effect Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
229940063683 taxotere Drugs 0.000 description 3
GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical class [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
150000001351 alkyl iodides Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
150000002148 esters Chemical group 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000000203 mixture Substances 0.000 description 2
125000001181 organosilyl group Chemical class [SiH3]* 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229910000105 potassium hydride Inorganic materials 0.000 description 2
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
238000011002 quantification Methods 0.000 description 2
229910052701 rubidium Inorganic materials 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229910001923 silver oxide Inorganic materials 0.000 description 2
239000000758 substrate Substances 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
RSOYRXBYZFBWFS-UHFFFAOYSA-N 1-methoxy-4-(methoxymethyl)benzene Chemical compound COCC1=CC=C(OC)C=C1 RSOYRXBYZFBWFS-UHFFFAOYSA-N 0.000 description 1
CRAJLXHBNCCDPK-UHFFFAOYSA-N 2,2,2-trichloroethyl hydrogen carbonate Chemical class OC(=O)OCC(Cl)(Cl)Cl CRAJLXHBNCCDPK-UHFFFAOYSA-N 0.000 description 1
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229930190007 Baccatin Natural products 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
102100037101 Deoxycytidylate deaminase Human genes 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101000955042 Homo sapiens Deoxycytidylate deaminase Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
108700041567 MDR Genes Proteins 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000004171 alkoxy aryl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000008051 alkyl sulfates Chemical class 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000003849 aromatic solvent Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
150000001638 boron Chemical class 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical group C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000002224 dissection Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000020680 filtered tap water Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
125000003106 haloaryl group Chemical group 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
GPKUICFDWYEPTK-UHFFFAOYSA-N methoxycyclohexatriene Chemical group COC1=CC=C=C[CH]1 GPKUICFDWYEPTK-UHFFFAOYSA-N 0.000 description 1
GQKZBCPTCWJTAS-UHFFFAOYSA-N methoxymethylbenzene Chemical compound COCC1=CC=CC=C1 GQKZBCPTCWJTAS-UHFFFAOYSA-N 0.000 description 1
UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical group COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
235000021395 porridge Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000005336 safety glass Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000002130 sulfonic acid ester group Chemical group 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
QWEJGTIVESCYNM-UHFFFAOYSA-N trimethyl-[2-(2-trimethylsilylethoxymethoxymethoxy)ethyl]silane Chemical compound C[Si](C)(C)CCOCOCOCC[Si](C)(C)C QWEJGTIVESCYNM-UHFFFAOYSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20010654A 1998-08-17 2001-02-07 Ny medisinsk anvendelse av 4α-acetoksy-2α-benzoyloksy-5β,20-epoksy-1β-hydroksy-7β,10β-dimetoksy-9-okso-11-taxen-13α-yl(2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylpropionat. NO327296B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98115401A EP0982027A1 (en)	1998-08-17	1998-08-17	Taxoid derivatives for treating abnormal cell proliferation of the brain
US9958198P	1998-09-08	1998-09-08
PCT/EP1999/006291 WO2000009120A1 (en)	1998-08-17	1999-08-13	New use of taxoid derivatives

Publications (3)

Publication Number	Publication Date
NO20010654D0 NO20010654D0 (no)	2001-02-07
NO20010654L NO20010654L (no)	2001-02-07
NO327296B1 true NO327296B1 (no)	2009-06-02

Family

ID=26149540

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010654A NO327296B1 (no)	1998-08-17	2001-02-07	Ny medisinsk anvendelse av 4α-acetoksy-2α-benzoyloksy-5β,20-epoksy-1β-hydroksy-7β,10β-dimetoksy-9-okso-11-taxen-13α-yl(2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylpropionat.

Country Status (19)

Country	Link
US (1)	US6346543B1 (et)
EP (1)	EP1109547A1 (et)
JP (1)	JP5354762B2 (et)
KR (1)	KR100710533B1 (et)
AU (1)	AU766168B2 (et)
BG (1)	BG65365B1 (et)
CA (1)	CA2340921C (et)
CZ (1)	CZ293959B6 (et)
EE (1)	EE04903B1 (et)
HU (1)	HU230235B1 (et)
ID (1)	ID27545A (et)
IL (1)	IL141238A0 (et)
ME (1)	ME00533B (et)
NO (1)	NO327296B1 (et)
NZ (1)	NZ509965A (et)
RS (1)	RS52011B (et)
SK (1)	SK285212B6 (et)
TR (1)	TR200100557T2 (et)
WO (1)	WO2000009120A1 (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP1020188A1 (en) *	1999-01-13	2000-07-19	Aventis Pharma S.A.	New use of taxoid derivatives
WO2001077137A1 (en) *	2000-04-12	2001-10-18	Human Genome Sciences, Inc.	Albumin fusion proteins
EP1401477A4 (en) *	2001-05-25	2005-02-02	Human Genome Sciences	CHIMIOKINE BETA-1 HYBRID PROTEINS
EP2277889B1 (en) *	2001-12-21	2014-07-09	Human Genome Sciences, Inc.	Fusion proteins of albumin and interferon beta
CA2484556A1 (en) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
EP1594530A4 (en)	2003-01-22	2006-10-11	Human Genome Sciences Inc	HYBRID PROTEINS OF ALBUMIN
FR2859996B1 (fr) *	2003-09-19	2006-02-03	Aventis Pharma Sa	Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR2926551A1 (fr) *	2008-01-17	2009-07-24	Aventis Pharma Sa	Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US8637466B2 (en)	2008-08-11	2014-01-28	Nektar Therapeutics	Multi-arm polymeric alkanoate conjugates
EA024186B1 (ru)	2009-10-29	2016-08-31	Авентис Фарма С.А.	Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты
WO2012088422A1 (en)	2010-12-22	2012-06-28	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en)	2010-12-22	2021-01-19	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
JP6025861B2 (ja)	2011-12-13	2016-11-16	アベンティス・ファーマ・ソシエテ・アノニム	カバジタキセルの結晶形およびこれを調製するための方法
JP2015509929A (ja) *	2012-02-10	2015-04-02	アベンティス・ファーマ・ソシエテ・アノニム	カバジタキセルの新規な小児への使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9102128A (es) *	1990-11-23	1992-07-08	Rhone Poulenc Rorer Sa	Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696459B1 (fr)	1992-10-05	1994-11-25	Rhone Poulenc Rorer Sa	Procédé de préparation de dérivés du taxane.
TW467896B (en)	1993-03-19	2001-12-11	Bristol Myers Squibb Co	Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
MA23823A1 (fr) *	1995-03-27	1996-10-01	Aventis Pharma Sa	Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en) *	1995-03-27	1998-12-08	Rhone-Poulenc Rorer, S.A.	Taxoids, their preparation and pharmaceutical compositions containing them
US5481018A (en)	1995-03-31	1996-01-02	The Dow Chemical Company	Amino nitrile intermediate for the preparation of alanine diacetic acid
FR2771092B1 (fr)	1997-11-18	1999-12-17	Rhone Poulenc Rorer Sa	Procede de preparation de derives de la classe des taxoides

1999
- 1999-08-11 US US09/371,838 patent/US6346543B1/en not_active Expired - Lifetime
- 1999-08-13 ID IDW20010379A patent/ID27545A/id unknown
- 1999-08-13 TR TR2001/00557T patent/TR200100557T2/xx unknown
- 1999-08-13 SK SK230-2001A patent/SK285212B6/sk not_active IP Right Cessation
- 1999-08-13 KR KR1020017001970A patent/KR100710533B1/ko not_active Expired - Lifetime
- 1999-08-13 RS YU7901A patent/RS52011B/sr unknown
- 1999-08-13 AU AU57419/99A patent/AU766168B2/en not_active Expired
- 1999-08-13 ME MEP-2008-893A patent/ME00533B/me unknown
- 1999-08-13 CA CA002340921A patent/CA2340921C/en not_active Expired - Lifetime
- 1999-08-13 EE EEP200100079A patent/EE04903B1/et unknown
- 1999-08-13 IL IL14123899A patent/IL141238A0/xx not_active IP Right Cessation
- 1999-08-13 JP JP2000564623A patent/JP5354762B2/ja not_active Expired - Lifetime
- 1999-08-13 NZ NZ509965A patent/NZ509965A/en not_active IP Right Cessation
- 1999-08-13 EP EP99944531A patent/EP1109547A1/en not_active Withdrawn
- 1999-08-13 WO PCT/EP1999/006291 patent/WO2000009120A1/en not_active Ceased
- 1999-08-13 CZ CZ2001604A patent/CZ293959B6/cs not_active IP Right Cessation
- 1999-08-13 HU HU0103748A patent/HU230235B1/hu unknown
2001
- 2001-02-07 NO NO20010654A patent/NO327296B1/no not_active IP Right Cessation
- 2001-02-16 BG BG105264A patent/BG65365B1/bg unknown

Also Published As

Publication number	Publication date
US6346543B1 (en)	2002-02-12
BG65365B1 (bg)	2008-04-30
HUP0103748A2 (hu)	2002-04-29
NO20010654D0 (no)	2001-02-07
CZ2001604A3 (en)	2001-06-13
NO20010654L (no)	2001-02-07
ME00533B (me)	2011-10-10
YU7901A (sh)	2003-12-31
JP5354762B2 (ja)	2013-11-27
AU5741999A (en)	2000-03-06
EP1109547A1 (en)	2001-06-27
RS52011B (sr)	2012-04-30
SK2302001A3 (en)	2001-09-11
EE200100079A (et)	2002-08-15
WO2000009120A1 (en)	2000-02-24
SK285212B6 (sk)	2006-09-07
KR20010085396A (ko)	2001-09-07
CA2340921C (en)	2009-01-06
NZ509965A (en)	2003-09-26
KR100710533B1 (ko)	2007-04-23
ID27545A (id)	2001-04-12
TR200100557T2 (tr)	2001-07-23
BG105264A (en)	2001-11-30
HU230235B1 (hu)	2015-10-28
CZ293959B6 (cs)	2004-08-18
WO2000009120A8 (en)	2001-04-05
IL141238A0 (en)	2002-03-10
HUP0103748A3 (en)	2003-01-28
AU766168B2 (en)	2003-10-09
CA2340921A1 (en)	2000-02-24
JP2002522490A (ja)	2002-07-23
EE04903B1 (et)	2007-10-15

Publication	Publication Date	Title
NO327296B1 (no)	2009-06-02	Ny medisinsk anvendelse av 4α-acetoksy-2α-benzoyloksy-5β,20-epoksy-1β-hydroksy-7β,10β-dimetoksy-9-okso-11-taxen-13α-yl(2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylpropionat.
US20210077625A1 (en)	2021-03-18	Ray tracing technique for wireless channel measurements
Pendri et al.	1998	Antitumor activity of paclitaxel-2′-glycinate conjugated to poly (ethylene glycol): a water-soluble prodrug
Huang et al.	2012	Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
CN101842392B (zh)	2014-08-27	非抗凝血剂的多糖组合物
US10016449B2 (en)	2018-07-10	Pharmaceutical compositions
EP4434546A1 (en)	2024-09-25	Novel acid-sensitive aptamer triptolide conjugate and application
CA3208210A1 (en)	2022-08-18	Sugar derived lipid nanomaterials and uses thereof
US20210205293A1 (en)	2021-07-08	Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
RU2398578C2 (ru)	2010-09-10	Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
WO2011063127A1 (en)	2011-05-26	Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US20120183976A1 (en)	2012-07-19	Methods of assessing activity of a polysaccharide composition
EP2632264A2 (en)	2013-09-04	Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
US12233087B2 (en)	2025-02-25	Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions
Li et al.	2025	A pH-responsive polycarbonate nanoplatform enables sequential drug release for enhanced apoptotic cascade synergy in non-small cell lung cancer therapy
US9833508B2 (en)	2017-12-05	Cancer therapeutics
JP2015091765A (ja)	2015-05-14	副作用のない抗癌剤
EA005135B1 (ru)	2004-12-30	Новое применение таксоидных производных
KR20230172544A (ko)	2023-12-22	면역기능적 담체, 사용 방법, 및 항종양 면역요법으로서의 조성물 물질
KR20220145757A (ko)	2022-10-31	암의 전이 억제 및 치료용 조성물
MXPA01001683A (en)	2001-11-21	New use of taxoid derivatives
Duncan et al.	2008	343 POSTER Preclinical validation of the TrpM8 ion channel as a cancer target
van Herpen et al.	2008	344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors
Katsila et al.	2008	Evaluation of gonadotropin-releasing hormone analogues in mice–pharmacokinetic studies and biomarker based efficacy by mass spetrometry
Musteata et al.	2006	Updates in diagnosis and treatment of chronic myeloid leukemia

Legal Events

Date	Code	Title	Description
2019-09-09	MK1K	Patent expired